Hepatorenal syndrome secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Sunny Kumar (talk | contribs) |
Sunny Kumar (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hepatorenal syndrome}} | {{Hepatorenal syndrome}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{SKA}} | ||
==Overview== | ==Overview== | ||
Revision as of 18:32, 5 December 2017
|
Hepatorenal syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hepatorenal syndrome secondary prevention On the Web |
|
American Roentgen Ray Society Images of Hepatorenal syndrome secondary prevention |
|
Risk calculators and risk factors for Hepatorenal syndrome secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sunny Kumar MD [2]
Overview
Secondary Prevention
Intravenous albumin
A randomized controlled trial found that intravenous albumin on the day of admission and on hospital day 3 can reduce renal impairment.[1]
Pentoxifylline
Pentoxifylline, phosphodiesterase inhibitor improves kidney functioning status in patients of Hepatorenal syndrome.[2]
References
- ↑ Sort P, Navasa M, Arroyo V; et al. (1999). "Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis". N. Engl. J. Med. 341 (6): 403–9. PMID 10432325.
- ↑ Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L; et al. (1999). "Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis". N Engl J Med. 341 (6): 403–9. doi:10.1056/NEJM199908053410603. PMID 10432325.